Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Fallowfield, Lesley; Francis, Adele (2016)
Publisher: American Medical Association (AMA)
Languages: English
Types: Article
Subjects: RC0254, R, RC0280.B8

Classified by OpenAIRE into

mesheuropmc: skin and connective tissue diseases
Importance: While the prevalence of ductal carcinoma in situ (DCIS) of the breast has increased substantially following the introduction of breast-screening methods, the clinical significance of early detection and treatment for DCIS remains unclear.\ud \ud Objective: To investigate the survival benefit of breast surgery for low-grade DCIS.\ud \ud Design, Setting, and Participants: A retrospective longitudinal cohort study using the Surveillance, Epidemiology, and End Results (SEER) database from October 9, 2014, to January 15, 2015, at the Dana-Farber/Brigham and Women’s Cancer Center. Between 1988 and 2011, 57 222 eligible cases of DCIS with known nuclear grade and surgery status were identified.\ud \ud Exposures: Patients were divided into surgery and nonsurgery groups.\ud \ud Main: Outcomes and Measures Propensity score weighting was used to balance patient backgrounds between groups. A log-rank test and multivariable Cox proportional hazards model was used to assess factors related to overall and breast cancer–specific survival.\ud \ud Results: Of 57 222 cases of DCIS identified in this study, 1169 cases (2.0%) were managed without surgery and 56 053 cases (98.0%) were managed with surgery. With a median follow-up of 72 months from diagnosis, there were 576 breast cancer–specific deaths (1.0%). The weighted 10-year breast cancer–specific survival was 93.4% for the nonsurgery group and 98.5% for the surgery group (log-rank test, P < .001). The degree of survival benefit among those managed surgically differed according to nuclear grade (P = .003). For low-grade DCIS, the weighted 10-year breast cancer–specific survival of the nonsurgery group was 98.8% and that of the surgery group was 98.6% (P = .95). Multivariable analysis showed there was no significant difference in the weighted hazard ratios of breast cancer–specific survival between the surgery and nonsurgery groups for low-grade DCIS. The weighted hazard ratios of intermediate- and high-grade DCIS were significantly different (low grade: hazard ratio, 0.85; 95% CI, 0.21-3.52; intermediate grade: hazard ratio, 0.23; 95% CI, 0.14-0.42; and high grade: hazard ratio, 0.15; 95% CI, 0.11-0.23) and similar results were seen for overall survival.\ud \ud Conclusions and Relevance: The survival benefit of performing breast surgery for low-grade DCIS was lower than that for intermediate- or high-grade DCIS. A prospective clinical trial is warranted to investigate the feasibility of active surveillance for the management of low-grade DCIS.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1.Dodwell D, Clements K, Lawrence G et al on behalf of the Sloane Project Steering Group. Radiotherapy following breast-conserving surgery for screen-detected ductal carcinoma in situ: indications and utilization in the UK. Interim findings from the Sloane Project. BJC; 2007; 97: 725-729 2. Sagara Y, Mallory MA, Wong S, et al. Survival Benefit of Breast Surgery for Low-Grade Ductal Carcinoma In Situ: A PopulationBased Cohort Study. JAMA Surg. 2015;150(8):739-745 3. Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. Independent UK Panel on Breast Cancer Screening.
    • The benefits and harms of breast cancer screening: an independent review. Lancet 2012;380 (9855):1778-1786.
    • 4. Jørgensen KJ and Gøtzsche P.C. Who evaluates public health programmes? A review of the NHS Breast Screening Programme.
    • J R Soc Med. 2010; 103 (1):14-20 5. Siobhan O'Connor Why Doctors Are Rethinking Breast-Cancer Treatment Oct. 12, Time Magazine 2015 6. Fallowfield L, Francis A, Catt S, Mackenzie M, Jenkins V. Time for a low-risk DCIS trial: harnessing public and patient involvement.
    • Lancet Oncol. 2012; 13(12):1183-1185.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article